IL6 and atrophic macular degeneration: A recent meta-analysis showed that a high level of plasma interleukin-6 (IL-6) is associated with neovascular AMD and geographic atrophy, suggesting that the late stages of AMD are accompanied by chronic low-grade inflammation and the therapeutic potential of targeting systemic IL-6 [22].